REDWOOD CITY, Calif.,
July 24, 2013
Genomic Health, Inc.
(Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Wednesday, July 31 at 4:30 p.m. Eastern Time to discuss its second quarter 2013 financial results. The call and webcast will follow the release of the second quarter financial results after market close.
Conference Call Details
To access the live conference call on
4:30 p.m. Eastern Time
via phone, please dial (877) 303-7208 from
the United States
or +1(224) 357-2389 internationally. Please dial in approximately ten minutes prior to the start of the call.
To access the live and subsequently archived webcast of the conference call, go to the
section of the company's website at
. Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.
About Genomic Health
, Inc. (NASDAQ:
) is a global healthcare company that provides actionable genomic information to personalize cancer treatment decisions. The company's lead product, the
Oncotype DX® breast cancer test
, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive
and has been shown to predict the likelihood of recurrence in
ductal carcinoma in situ (DCIS)
. In addition to this widely adopted test,
Oncotype DX colon cancer test
, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with
stage II and stage III
disease and the Oncotype DX prostate cancer test, which predicts disease aggressiveness in men with low risk disease. As of March 31, 2013, more than 19,000 physicians in over 70 countries had ordered more than 350,000 Oncotype DX tests. Genomic Health has a robust pipeline focused on developing tests to further optimize the treatment of breast, colon and prostate cancers, as well as the treatment of renal cancer. The company is based in
, California with European headquarters in Geneva, Switzerland. For more information, please visit,
and follow the company on Twitter:
. To learn more about
Oncotype DX tests